Tower Research Capital (TRC)’s Bone Biologics BBLG Stock Holding History
Bought
Maintained
Sold
Other funds holding BBLG
Tower Research Capital (TRC)'s BBLG Position: Q3 2026 in Review
Tower Research Capital (TRC) increased its Bone Biologics (BBLG) stake by 15% in Q3 2026, buying an estimated $238 and bringing the position to 2,244 shares worth $1.11K. The position accounts for ﹤0.01% of the portfolio, ranked #5374.
Tower Research Capital (TRC) first reported a position in BBLG in Q2 2022 and has held it in 18 quarters since. The position peaked at $9.05K in Q1 2024. 8 funds tracked by Wall St. Rank hold BBLG as of Q3 2026.
- Tower Research Capital (TRC) held 2,244 shares of Bone Biologics worth $1.11K as of Q3 2026.
- Tower Research Capital (TRC) bought 291 Bone Biologics shares in Q3 2026, an estimated $238.
- Bone Biologics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q3 2026, its #5374 holding.
- Tower Research Capital (TRC) first reported a position in Bone Biologics in Q2 2022 and has held it in 18 quarters since.
- Tower Research Capital (TRC)'s Bone Biologics position peaked at $9.05K in Q1 2024.
- 8 funds tracked by Wall St. Rank held Bone Biologics as of Q3 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q3 2026, filed 16 Nov 2026.